Diligence memo · auto-generated · as of July 2, 2026
QR Pharma, Inc.
QR Pharma, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
QR Pharma, Inc. operates in Pharmaceuticals, based in BERWYN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
QR Pharma, Inc. has raised $5.1M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.1M on 2015-05-22.
Most recent recorded round closed around 2023-04-07.
Valuation (modeled)modeled
Provath models QR Pharma, Inc. at approximately $9.6M (range $805K–$36M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 3.2 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 42% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.